The outcome of the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG) clearly showed that SGLT2 inhibitors suppress pathologies in heart failure1. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.